Oruka Therapeutics Inc

Oruka Therapeutics Inc (ABIO) Financials

ABIO Profitability and Margins

Evaluating the bottom line, ARCA Biopharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -20.05%, provide a clear picture of how effectively ABIO converts its operational activities into shareholder value.

ABIO Comparative Benchmarking

In the context of the broader market, ABIO competes directly with industry leaders such as VTVT and BRNS. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ABIO's gross margin of N/A stands against VTVT's N/A and BRNS's N/A. Such benchmarking helps identify whether ARCA Biopharma Inc is trading at a premium or discount relative to its financial performance.

Financials

FY2024Q3
YoY:
+1414.35%
-29.33M
Operating Profit
FY2024Q3
YoY:
+1910.04%
-28.62M
Net Income after Tax
FY2024Q3
YoY:
+1810.00%
-1.91
EPS - Diluted
FY2023Q4
YoY:
-29.32%
-1.06M
Free Cash Flow

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis